Stroke is a devastating complication of transcatheter aortic-valve implantation (TAVI), compromising its remarkable ...

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Intracranial aneurysms are common, and the risk of rupture is influenced by size, location, morphology, and factors such as ...

We conducted a phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial that included 11 groups as two cohorts. Participants with obesity (obesity cohort) were randomly assigned ...

One of the more difficult decisions for patients with poorly controlled type 2 diabetes, as well as for their clinicians, is ...

Among 485 patients who were MRD-negative at 10 −5 sensitivity after induction, a premaintenance MRD-negative status at 10 −6 sensitivity occurred in 86% in the ASCT group and in 84% in the Isa ...

A total of 415 patients were assigned to cemiplimab (209) or placebo (206). The median follow-up was 24 months. Cemiplimab was superior to placebo with respect to disease-free survival (24 vs. 65 ...

Ten men with severe hemophilia B received a single intravenous infusion of the scAAV2/8-LP1-hFIXco vector in one of three dose groups (low-dose: 2×10 11 vector genomes [vg] per kilogram of body ...

Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin–proteasome system.In this phase 3, open-label, randomized ...

As physicians continue to debate the role of race in clinical algorithms, the unusual history of debates over race-specific anemia diagnosis may be instructive.